Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 49Nivolumab 21Cisplatin 11Cetuximab 11Carboplatin 10Paclitaxel 8Gemcitabine 8Docetaxel 8atezolizumab 7Ipilimumab 7Cyclophosphamide 7spartalizumab 6durvalumab 6Fluorouracil 6Capecitabine 6fludarabine 5avelumab 5Albumin-Bound Paclitaxel 5cemiplimab 4Trastuzumab 4Taxes 4Oxaliplatin 4Leucovorin 4Bevacizumab 4130-nm albumin-bound paclitaxel 4tremelimumab 3tisotumab vedotin 3aldesleukin 3Specimen Handling 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × prexasertib × Gastrointestinal × Clear all
NCT01115790 2016-05-10

A Phase 1 Study in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
150 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡